Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib vs temozolomide in newly diagnosed MGMT-unmethylated glioblastoma
2024-513077-48-00Phase 3Authorised
- Sponsor
- NeuroTrials
- Start
- Dec 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) comparing Niraparib arm with Temozolomide arm (2 arms). Primary endpoint: Overall survival. Planned start Dec 2024; status: authorised.
02
Drugs
niraparibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-513077-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513077-48-00.